By G HossainPosted on April 24, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns. Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer Post navigation Avalyn seeks public debut to support new lung drug formulationsDaiichi Sankyo shares slip after delaying annual earnings report